Probiotics, Prebiotics & Synbiotics

What's covered

By the end of this module you will be able to

• L01Define probiotics, prebiotics, synbiotics, and postbiotics with correct terminology.
• L02Explain why probiotic effects are strain-specific and not generalizable across species.
• L03Identify conditions with high-quality RCT evidence for specific probiotic strains.
• L04Critically evaluate consumer probiotic marketing claims.

What you should walk away believing

What this means for you

The probiotic-for-everything patient

Strain-by-strain screening outcomes

Six worked cases mapped onto the 6-point high-risk screen — each shows the patient profile, the strain considered, what the screen returned, the prescribing decision, and the teaching point.

Post-prescription monitoring & follow-up — high-risk patients

When a probiotic is prescribed to a moderate- or high-risk patient (any positive item on the 6-point screen except severe pancreatitis, which is do-not-prescribe), the prescription is only the start. Schedule the visits below at the time the probiotic is started, not after a problem appears. Each visit has a defined assessment set, a labs trigger, and an explicit escalation criterion that hands off to the follow-up infection protocol.

1. 00

   Visit 0 — Baseline (day of prescription)

   At the prescribing encounter.
   Assessments

   • →Re-confirm the 6-point screen and document indication, strain, lot number, dose, route, start date, and the planned hard stop date.
   • →Patient/caregiver counselling on red-flag symptoms (printed Patient Guidance handout).
   • →Add a structured chart flag: 'On probiotic [strain] from [date]; reassess [date]; STOP if red flags.'
   • →If a central line is present and the strain is acceptable (Bifidobacterium-only, GMP), document line-care reinforcement and aerosol precautions when handling sachets/capsules.
   Labs / tests

   • ·Baseline CBC with differential, CRP, lactate (and D-lactate if SBS).
   • ·If immunocompromised: latest CD4/neutrophil count and immunosuppressant levels in the chart.
   Escalation

   Any baseline finding suggesting active infection → defer probiotic, re-screen.

2. 01

   Visit 1 — Early tolerance check (72 h)

   Phone or secure-message review at 48–72 h.
   Assessments

   • →Adherence (taken as prescribed? with food? line precautions followed?).
   • →Tolerability: bloating, flatulence, change in stool frequency/consistency.
   • →Any new fever, rigors, malaise, line-site change, neurological symptoms, or rash?
   • →Reinforce red-flag teaching and the stop-and-call rule.
   Escalation

   Fever ≥ 38.0 °C, rigors, hypotension, line-site inflammation, encephalopathy/ataxia → STOP probiotic, draw blood cultures (peripheral + each lumen), trigger the follow-up infection protocol.

3. 02

   Visit 2 — Two-week safety review (day 14 ± 2)

   In-person or telehealth visit.
   Assessments

   • →Symptom diary review (GI, systemic, neurological).
   • →Targeted exam: temperature, line site (if present), heart auscultation (especially valve patients), abdominal exam.
   • →Confirm the patient still has the original product and verify the lot number against the chart.
   • →Indication-specific endpoint check (e.g. Bristol stool chart for AAD; IBS-SSS for IBS; NEC scoring in NICU).
   Labs / tests

   • ·Repeat CBC + CRP if any inflammatory symptom or unexplained fatigue.
   • ·Blood cultures × 2 if any unexplained fever in the prior 14 days, even if afebrile at visit.
   Escalation

   New murmur on auscultation in a valve patient → urgent TTE/TEE + blood cultures × 2 from independent sites; do not wait.

4. 03

   Visit 3 — Mid-course efficacy & risk reassessment (week 4)

   Day 28 ± 3.
   Assessments

   • →Efficacy: validated symptom score for the indication; if no measurable benefit, plan to STOP at the hard stop date.
   • →Risk re-screen: did the patient acquire a new line, start steroids/biologics, have surgery, become pregnant, or develop new GI compromise?
   • →Strain-product audit: still the same strain and lot? Any product recalls posted (FDA recall list, RASFF alerts) for this lot?
   • →Counselling refresh on red flags and reporting pathways.
   Escalation

   Any new high-risk factor → STOP probiotic, document the risk transition, and only restart after fresh screen-and-counsel cycle. Recall alert against the lot → STOP, retain the product, file a MedWatch/RASFF report and notify the manufacturer.

5. 04

   Visit 4 — End-of-course / hard stop (week 6–8 or per protocol)

   At the planned stop date set at Visit 0.
   Assessments

   • →Decision: STOP, EXTEND with a new defined endpoint, or ESCALATE workup if symptoms persist.
   • →Indication outcome documented in the chart (worked / partial / no benefit / harm).
   • →If continuing, reset the hard stop date and the visit cadence.
   • →Update the chart flag — either remove or re-date.
   Labs / tests

   • ·Repeat CBC + CRP if any prior abnormality or persistent symptom.
   • ·Optional colonization verification (strain-specific qPCR or shotgun metagenomics) if the question is engraftment-vs-efficacy in a long-term user.
   Escalation

   Persistent unexplained symptoms after stopping → consider AE workup; report via MedWatch / national authority even if non-serious.

6. 05

   Visit 5 — Post-stop surveillance (4 weeks after stop)

   4 weeks after the last dose.
   Assessments

   • →Late-onset bacteremia/endocarditis surveillance: ask about fevers, night sweats, weight loss, embolic phenomena, new fatigue.
   • →Confirm chart 'No probiotics' flag is in place if a true contraindication emerged.
   • →If the patient was on a Bifidobacterium-only product because of high-risk status, document whether the indication has resolved or re-prescription is appropriate.
   Escalation

   Late fever or new murmur → blood cultures × 2 + echocardiography; treat with the assumption that the prior probiotic organism is the cause until proven otherwise.

Case-based: triage, document, notify

Five worked adverse-event triage walkthroughs. Each one moves left-to-right through the same loop: triage in the first hour → exactly what to put in the chart → exactly who to notify and on what timeline. The 'pitfall' line is the most common reason these cases fail audit.

What the data says

Test yourself

High-risk patient screening

Case-based AE triage quiz — baseline competency check

AE reporting decision tree

Graded triage challenges (partial credit)

Quick triage flowchart — severity to documentation & notifications

AE reporting playbook by severity — fields, who, when, where

Branching case — your decisions change the patient's trajectory

Notification templates — clinician, IPC, pharmacovigilance

Suspected probiotic adverse event — [Patient initials, MRN] — [Strain] — action requested

Hi Dr [Last name],

I am contacting you about a suspected adverse event linked to a probiotic you prescribed (or that the patient self-initiated under your care).

PATIENT
• Initials / MRN: [____]
• Age / sex / weight: [____]
• Care setting now: [outpatient / ED / inpatient / ICU]

PRODUCT
• Brand: [____]   Manufacturer: [____]
• Strain(s) on label: [Genus species + designation, e.g. Saccharomyces boulardii CNCM I-745]
• Lot / batch: [____]   Expiry: [____]   CFU/dose: [____]
• Dose, route, frequency: [____]
• First dose: [date]   Last dose: [date/time]   Duration: [days]

EVENT
• Symptom onset (date/time): [____]
• Time from last dose to onset: [____]
• Symptoms / vitals: [____]
• Seriousness: [non-serious / serious — hospitalisation / life-threatening / other]
• Dechallenge response so far: [improved / unchanged / worsened / NA]

ACTIONS TAKEN
• Probiotic STOPPED at [date/time]; remaining doses quarantined.
• Initial workup: [cultures / labs / imaging ordered].
• Empiric therapy started: [drug, dose, route] — note vancomycin AVOIDED if Lactobacillus is suspected (intrinsic resistance).

REQUESTED FROM YOU
1. Confirm the probiotic is HARD-STOPPED in the medication list and an allergy-style flag is added naming the strain.
2. Confirm or modify the empiric antimicrobial plan.
3. Approve referral / escalation as needed (ID, IPC, ICU).
4. Acknowledge that an AE report will be filed (FDA MedWatch / FDA SRP / EU national authority / MHRA Yellow Card / Livsmedelsverket — as applicable).

I will document this conversation in the chart and copy you on the AE report.

Thank you,
[Your name, role, contact]

IPC notification — suspected probiotic-related infection — [Ward / unit] — [Strain]

Hello IPC team,

Notifying you of a suspected probiotic-related infection that may require unit-level review and lot quarantine.

PATIENT (de-identified)
• Ward / bed: [____]
• Risk factors at exposure: [central line / immunosuppression / prosthetic valve / SBS / NICU / other]

PRODUCT
• Brand + manufacturer: [____]
• Strain(s): [____]
• Lot / batch: [____]   Expiry: [____]
• How administered on the unit: [intact capsule PO / capsule opened for NG / sachet / liquid]

CLINICAL SIGNAL
• Onset (date/time): [____]
• Cultures: [site, organism, date — e.g. blood culture +ve for Saccharomyces, day 5]
• Strain attribution status: [pending / WGS sent / ANI vs product isolate = __%]
• Resistance gene scan requested: [Y/N — vanA/B, ermB, tetM/W, aac(6′)-aph(2″)]

REQUESTED FROM IPC
1. Quarantine remaining stock of the implicated lot on the unit and in pharmacy.
2. Audit ward practice — specifically capsule-opening / sachet handling near central lines and shared patient bays.
3. Contact tracing for other patients on the unit who received the same lot in the past [14] days.
4. Coordinate with microbiology to send a re-isolated colony from the product to the reference lab for ANI confirmation.
5. Decide whether a unit-level practice change or temporary product hold is warranted pending investigation.
6. Open an incident ticket and link it to the patient AE record.

Parallel actions already underway:
• Probiotic stopped, allergy-style flag added.
• Patient AE report being filed (FDA MedWatch / FDA SRP / RASFF / EU NCA / MHRA / Livsmedelsverket — as applicable).
• Manufacturer pharmacovigilance to be notified once strain attribution status is known.

Available to discuss anytime.
[Your name, role, pager / phone]

Probiotic adverse event report — [Brand] — Lot [____] — [Strain] — [Seriousness]

Pharmacovigilance / regulator submission — narrative section

1. REPORTER
   Name, role, institution, country, contact email/phone:
   [____]

2. PATIENT (de-identified)
   Age, sex, weight, pregnancy status, relevant comorbidities and concomitant medications:
   [____]
   Risk factors at exposure (central line / immunosuppression / prosthetic valve / SBS / severe pancreatitis / preterm / other):
   [____]

3. PRODUCT
   Brand: [____]
   Manufacturer: [____]
   NDC / GTIN / EAN: [____]
   Country purchased: [____]
   Lot / batch number: [____]   Expiry: [____]
   CFU per dose (label): [____]
   Dosage form: [____]
   Storage at point of use: [____]
   Remaining product retained for testing: [Y/N]

4. STRAIN(S) — full taxonomic designation for every strain on the label
   1. [Genus species, strain designation (e.g. CNCM I-745), CFU contribution]
   2. [____]
   3. [____]

5. EXPOSURE
   Indication: [____]
   Dose, frequency, route: [____]
   First dose: [date]   Last dose: [date/time]   Total duration: [days]
   Co-administered antibiotics / supplements / drugs: [____]

6. EVENT
   Onset (date/time): [____]
   Time from first dose to onset: [____]
   Time from last dose to onset: [____]
   Symptoms with severity 1–10: [____]
   Vital signs at presentation: [____]
   Seriousness criteria (tick all): [death / life-threatening / hospitalisation / persistent disability / congenital anomaly / required intervention to prevent permanent impairment / other medically important]
   Outcome: [resolved / ongoing / sequelae / fatal]

7. DIAGNOSTICS & MICROBIOLOGY
   Cultures, imaging, labs: [____]
   Strain ID method: [MALDI / 16S / WGS]
   ANI vs re-isolated product colony (≥ 99.9% = identity): [____%]
   Resistance genes detected: [vanA/B, ermB, tetM/W, aac(6′)-aph(2″) / none]

8. MANAGEMENT
   Probiotic stopped (date/time) and dechallenge response: [____]
   Empiric antimicrobials (drug, dose, route, duration) — vancomycin AVOIDED for Lactobacillus: [____]
   Source control (line removal, drainage, surgery): [____]
   Supportive care / ICU interventions: [____]

9. CAUSALITY ASSESSMENT (WHO-UMC)
   [certain / probable / possible / unlikely / unassessable]
   Reasoning: [time relationship, dechallenge, rechallenge, alternative explanations, strain identity]

10. PARALLEL NOTIFICATIONS
    [Internal IPC / pharmacy / AMR stewardship — date]
    [Manufacturer pharmacovigilance — date, reference]
    [Other regulators — channel, date, reference]

I am happy to provide the full AE report template (PDF/CSV), patient isolate, and a re-isolated product colony on request. The implicated lot has been quarantined.

[Your name, role, institution, contact]

Spaced review

Key terms & abbreviations

Probiotic

Live microorganisms that, when administered in adequate amounts, confer a health benefit on the host (WHO/FAO definition).

Prebiotic

A substrate that is selectively utilized by host microorganisms conferring a health benefit (ISAPP definition).

Synbiotic

A mixture comprising live microorganisms and substrate(s) selectively utilized by host microorganisms.

Postbiotic

A preparation of inanimate microorganisms and/or their components that confers a health benefit.

Colonization verification

Testing whether an administered probiotic strain has successfully engrafted in the host, using strain-specific qPCR, metagenomics, or WGS of re-isolated colonies.

StrainPhlAn

Bioinformatics tool for strain-level profiling from shotgun metagenomic data, enabling detection of specific probiotic strains in complex communities.

Pharmacovigilance

Science and activities relating to the detection, assessment, understanding, and prevention of adverse effects of pharmaceutical products — largely absent for probiotic supplements.

D-lactic acidosis

Metabolic acidosis caused by bacterial D-lactate production, seen with Lactobacillus probiotics in short bowel syndrome — causes encephalopathy and ataxia.

RASFFRASFF

EU Rapid Alert System for Food and Feed — used for reporting contamination events in food products including probiotic supplements.

PROPATRIA trial

2008 Lancet RCT (n=296) of multi-strain probiotic prophylaxis in severe acute pancreatitis showing increased mortality (16% vs 6%) — established absolute contraindication in this population.

High-risk patient screening

Structured pre-prescription assessment for probiotic contraindications: central venous access, immunosuppression, prosthetic valves, GI mucosal breach, prematurity, and strain-population fit.

MedWatchFDA

FDA's voluntary adverse event reporting program (Forms 3500/3500B) for drugs, biologics, devices, and dietary supplements — the primary US channel for probiotic AE reports.

FDA Safety Reporting PortalSRP

Online portal for mandatory reporting of serious adverse events associated with dietary supplements (including probiotics) under the Dietary Supplement and Nonprescription Drug Consumer Protection Act.

Adverse EventAE

Any untoward medical occurrence in a patient temporally associated with the use of a product, whether or not considered causally related.

Serious Adverse EventSAE

AE that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, causes persistent disability, congenital anomaly, or requires intervention to prevent permanent impairment.

EU Novel Food Regulation 2015/2283

EU framework requiring pre-market authorization and post-market monitoring for foods (including probiotic strains) without significant consumption history in the EU before 15 May 1997.

Lot traceability

Ability to link a specific batch of a probiotic product to manufacturing records and downstream consumers — essential for AE investigation, contamination tracing, and recall execution (RASFF, FDA recalls).

EFSA QPSQPS

European Food Safety Authority 'Qualified Presumption of Safety' list of microbial species considered safe for food/feed use — the EU-level baseline for probiotic strain acceptability.

Yellow Card scheme

UK MHRA's national pharmacovigilance reporting system; in the UK, suspected probiotic-related AEs (especially in medicines or food supplements with claims) can be reported via the Yellow Card site.

ANIANI

Average Nucleotide Identity — pairwise genome comparison metric; ≥99.9% between a patient isolate and a re-isolated product colony confirms probiotic strain identity for attribution of infection.

CRBSICRBSI

Catheter-related bloodstream infection. IDSA guidance directs early line removal for fungemia, persistent bacteremia >72 h on appropriate therapy, septic shock, or evidence of metastatic infection.

Intrinsic vancomycin resistance

Chromosomally encoded resistance present in many Lactobacillus rhamnosus and L. casei strains — empiric vancomycin will fail; use ampicillin/penicillin G ± gentamicin pending AST.

EARS-NetEARS-Net

ECDC European Antimicrobial Resistance Surveillance Network — destination for resistance-gene findings of public-health relevance from probiotic-related isolates.

Optional deeper dive

• Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features — Zmora N et al., Cell 2018↗
• AGA Clinical Practice Guidelines on the Role of Probiotics in GI Disorders — Su GL et al., Gastroenterology 2020↗

Clinical aids & handouts

• Probiotic Safety Monitoring Checklist

  Two-page clinical visit aid: pre-prescription screening, in-visit monitoring, AE triage, and reporting pathways (MedWatch, RASFF, Yellow Card).

  PDF
• Patient Guidance — Who Should Avoid Probiotics & Red-Flag Symptoms

  Two-page plain-language sheet for patients: who should avoid probiotics or use them with caution, red-flag symptoms that warrant emergency or same-day clinician contact, what to do before calling, and how to report a side effect (MedWatch, RASFF, Yellow Card, Livsmedelsverket).

  PDF
• Adverse Event Report — Documentation Template (PDF)

  Five-page printable AE intake form: reporter & patient identifiers, full strain-level product identification (brand, manufacturer, lot, expiry, CFU, dosage form, storage), dosing & exposure window, risk factors, chronological event timeline, symptoms & seriousness criteria, diagnostics & microbiology (culture, ANI, resistance genes), management, causality, and a regulatory routing checklist (MedWatch, FDA SRP, RASFF, EU NCA, MHRA Yellow Card, Livsmedelsverket, Läkemedelsverket, manufacturer PV, internal IPC/AMR, EARS-Net/CDC AR Lab Network).

  PDF
• Adverse Event Report — Structured Intake (CSV)

  Machine-readable CSV companion with the same fields as the PDF template — strain, lot number, dose, timeline, symptoms, diagnostics, causality, and reporting channels — for import into EHR pharmacovigilance modules, REDCap, or spreadsheet workflows.

  PDF
• AE Documentation Checklist (one-glance tick sheet)

  Two-page completeness checklist organised in 12 sections (reporter, product, strain, dose, risk factors, timeline, symptoms, diagnostics, management, causality, reporting channels, post-report actions). Tick every item before submitting an AE report — missing strain, lot, or timing data is the single most common reason a probiotic AE report is rejected.

  PDF